• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
  • approach
  • pipeline
  • news & insights
    • presentations
    • press releases
    • references (PRL-02)
    • references (CGS-200-5)
  • careers
  • contact
  • Menu Menu
  • newsworthy &
    insightful

    Stay updated and informed about all things Propella.

Presentation at the Annual Meeting of the American College of Rheumatology (November 12, 2019; Atlanta, GA): A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

Propella Therapeutics, Inc. presented “A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)” at the Annual Meeting of the American College of Rheumatology in Atlanta, GA on November 12, 2019.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 neil https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg neil2019-11-12 19:45:002022-09-12 13:09:17Presentation at the Annual Meeting of the American College of Rheumatology (November 12, 2019; Atlanta, GA): A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 altusdevsite_4grsdf https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg altusdevsite_4grsdf2019-10-29 18:25:002021-09-09 15:22:45Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting

Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 altusdevsite_4grsdf https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg altusdevsite_4grsdf2018-07-16 19:58:222021-09-09 15:22:52Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin

Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200

Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 altusdevsite_4grsdf https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg altusdevsite_4grsdf2018-06-11 07:58:232021-09-09 15:22:59Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
Page 7 of 7«‹567

categories

  • presentations
  • press releases
  • references (CGS-200-5)
  • references (PRL-02)
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • careers
  • contact
© 2020-2023 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top